To support the above data, we evaluated frequencies of IFN-γ-producing naïve (CD45RA+CCR7+CD28+CD95−) CD4+ T cells in a different cohort of 10 patients with active TB before the initiation of therapy (TB-0), compared with blood samples from the same patients taken 6 months later, i.e., at the end of therapy (TB-6). This evidence concerns the gene FAS and tuberculosis.